Trial Profile
Treatment of IgG4-Related Disease With Revlimid and Rituximab: The TIGR2 Trial
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Jul 2019
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Rituximab (Primary)
- Indications Autoimmune disorders
- Focus Therapeutic Use
- Acronyms TIGR2
- 03 Jul 2019 Status changed from active, no longer recruiting to completed.
- 08 Feb 2019 Status changed from recruiting to active, no longer recruiting.
- 12 Sep 2016 Status changed from not yet recruiting to recruiting.